iqo transit smoker risk youth appeal
believ altria deliv double-digit ep growth next year
long-term growth target driven price tax save manag spend share
buyback fall interest expens consid growth attract especi
dividend yield believ altria proactiv remov pod-bas flavor e-
vapor product market help align object fda goal may also
help facilit iqo approv believ littl youth appeal rais
ep ep maintain target
potenti new normal categori declin still manag altria recogn
us cigarett categori declin wors histor pace
recent part higher ga price also acceler growth e-vapor
howev still appear comfort abil manag ep growth algorithm
given variou lever price remain key driver particular altria two
consecut quarter price gain ahead histor averag
altria vapor action align fda goal may help pave way iqo
perceiv increas youth nicotin use co-incid growth flavor e-vapor
pod altria remov pod-bas e-vapor product flavor cig-a-lik product
market altria believ measur may help curb youth use also
reinforc regulatori leadership posit fda publicli align object
fda goal reduc youth use could potenti facilit iqo approv
product believ littl youth non-smok appeal tobacco-
base yucki non-smok limit tobacco flavor tobacco menthol
iqo help support long-term bullish outlook iqo get approv
us launch expect altria built least three iqo launch scenario
allow scale need lead market depend consum respons
price market approach etc still subject test market result time
iqo market author potenti reduc risk claim unknown
manag readi launch soon author given pack product
ship clear custom get shelf like take month
see low risk ep growth outlook believ ep growth
ep growth attract achiev tax reform big
driver near-term earn growth cash still grow commensur give
altria flexibl variou ep growth lever strong doubl digit dividend growth
look like versu altria typic august increas dividend growth
expect mirror ep growth pay investor robust earn growth momentum
unfavor regul disrupt excis tax hike gain illicit trade risk profit
altria commerci tobacco product us brand like marlboro skoal
intra-day price
price target
ep current multipl
ep expect altria deliv
three-year averag sale growth
revenu exclud excis tax
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
interest
swedish match launch zyn late us oral nicotin product similar snu
without tobacco avoid teeth discolor small compound monthli
sale growth chart pace far behind juul vapor sale store
presenc rel high annual pace retail sale per
store estim could half per-stor annual sale larg lead moist
snuff smokeless product suggest sale could much signific distribut grow
like follow capac expans swedish match invest new capac
brand product similar zyn nicotin pouch brand us believ
own inter-continent cigar/dannemann small privat tobacco compani zyn current
momentum proxi altria want similar offer portfolio without lengthi
fda approv process might consid ad brand like portfolo particularli zyn
pose risk copenhagen moist snuff momentum current limit distribut
us believ altria could use distribut market muscl grow brand
page
excis tax rev
good
cog percent sale
net incom attrib noncontrol int
net incom attrib altria
earn attribut share-bas award
current disclosur inform compani found www piperjaffray com/researchdisclosur
